World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board
/Feb. 04
2021
SAN DIEGO and VANCOUVER, BC, Feb. 4, 2021 - PhoenixMD, an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.
Read the story here